Company: SPEG
Filing Date: 2025-06-26
Form Type: S-1/A
Source: 0001213900-25-058468
Chunk: 234

Company: Silver Pegasus Acquisition Corp.
Filing Date: 2025-06-26
Form: S-1/A
Chunk 234
---
 by which it has to consummate a business combination from to September30, 2024. until March31, 2025 to consummate a business combination after its 2 ndExtension Meeting, the holders of 323,637 SKGR ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.31966896 per share, for an aggregate redemption amount of approximately $3,663,463.70. 143 SES AI Corp.Since March 2022, Mr.Noonen has served as a director of SES AI Corp. (NYSE: “ SES”), engaged in the development and production of high -performanceLi -Metalrechargeable battery technology for electric vehicles, and serves on the Audit Committee and Compensation Committee. SES consummated a business combination with Ivanhoe Capital Acquisition Corp., a SPAC (“Ivanhoe”), in February 2022. On January11, 2021, Ivanhoe consummated its initial public offering of 27,600,000 units, including the issuance of 3,600,000 Units as a result of the underwriters’ exercise of their over -allotmentoption in full. Each Unit consists of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), and one -thirdof one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $276,000,000. On February1, 2022, Ivanhoe had a special meeting to approve its business combination and a total of 22,455,850 Class A Ordinary Shares (81% of the outstanding Class A Ordinary Shares) were presented for redemption in connection with the General Meeting leaving approximately $51.45million remaining in Ivanhoe’s trust account following Redemptions. Atlantic Coastal Acquisition Corp. II (ACAB)Mr.Eisenberg currently serves on the Board of Directors of NASDAQ -listedbiotechnology company AbPro). AbPro had merged with ACAB, where from 2021 through 2024, Mr.Eisenberg served as a Director and Chief Strategy Officer. ACAB consummated its initial public offering on January19, 2022 generating gross proceeds of $300million with a deadline